Biologicals for the prevention of anaphylaxis

Tanno, Luciana Kase; Demoly, Pascal

doi:10.1097/aci.0000000000000737

Cited by 8 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For some patients, food desensitization may benefit from the addition of biologicals as adjunctive therapy (NCT04984876) 173–175 . Currently, multiple studies are using omalizumab or dupilumab either alone or in combination with OIT (NCT04045301, NCT03679676, NCT03881696, and NCT04037176).…”

Section: Updates On Clinical Treatment Approachesmentioning

confidence: 99%

“…172 For some patients, food desensitization may benefit from the addition of biologicals as adjunctive therapy (NCT04984876). [173][174][175] Currently, multiple studies are using omalizumab or dupilumab either alone or in combination with OIT (NCT04045301, NCT03679676, NCT03881696, and NCT04037176). Although there was interest in the effect of probiotic adjuvants on OIT, the effectiveness of these additions remains to be seen.…”

Section: Update S On Clini C Al Tre Atment a Pproache Smentioning

confidence: 99%

See 1 more Smart Citation

An update on recent developments and highlights in food allergy

Locke

Hung

Upton

et al. 2023

Allergy

View full text Add to dashboard Cite

While both the incidence and general awareness of food allergies is increasing, the variety and clinical availability of therapeutics remain limited. Therefore, investigations into the potential factors contributing to the development of food allergy (FA) and the mechanisms of natural tolerance or induced desensitization are required. In addition, a detailed understanding of the pathophysiology of food allergies is needed to generate compelling, enduring, and safe treatment options. New findings regarding the contribution of barrier function, the effect of emollient interventions, mechanisms of allergen recognition, and the contributions of specific immune cell subsets through rodent models and human clinical studies provide novel insights. With the first approved treatment for peanut allergy, the clinical management of FA is evolving toward less intensive, alternative approaches involving fixed doses, lower maintenance dose targets, coadministration of biologicals, adjuvants, and tolerance‐inducing formulations. The ultimate goal is to improve immunotherapy and develop precision‐based medicine via risk phenotyping allowing optimal treatment for each food‐allergic patient.

show abstract

Section: Updates On Clinical Treatment Approachesmentioning

confidence: 99%

Section: Update S On Clini C Al Tre Atment a Pproache Smentioning

confidence: 99%

An update on recent developments and highlights in food allergy

Locke

Hung

Upton

et al. 2023

Allergy

View full text Add to dashboard Cite

show abstract

“…132 For some patients, food desensitization may benefit from the addition of biologicals as adjunctive therapy. [133][134][135] Currently, multiple studies are using omalizumab or dupilumab either alone or in combination with OIT (NCT04045301, NCT03679676, NCT03881696, and NCT04037176). Although there was interest in the effect of probiotic adjuvants on OIT, the effectiveness of these additions remains to be seen.…”

Section: Updates On Clinical Treatment Approachesmentioning

confidence: 99%

An update on recent developments and highlights in food allergy

Locke

Hung

Upton

et al. 2023

Preprint

View full text Add to dashboard Cite

While both the incidence and general awareness of food allergies is increasing, the variety and clinical availability of therapeutics remain limited. Therefore, investigations into the potential factors contributing to the development of food allergy and the mechanisms of natural tolerance or induced desensitization are required. In addition, a detailed understanding of the pathophysiology of food allergies is needed to generate compelling, enduring, and safe treatment options. New findings regarding the contribution of barrier function, the effect of emollient interventions, mechanisms of allergen recognition, and the contributions of specific immune cell subsets through rodent models and human clinical studies provide novel insights. With the first approved treatment for peanut allergy, the clinical management of food allergy is evolving towards less intensive, alternative approaches involving fixed doses, lower maintenance dose targets, co-administration of biologicals, adjuvants, and tolerance-inducing formulations. The ultimate goal is to improve immunotherapy and develop precision-based medicine via risk phenotyping allowing optimal treatment for each food-allergic patient.

show abstract

“…It is currently FDA approved for the treatment of moderate to severe allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps [26]. It is the most prevalently used and most widely studied biologic in the prevention of anaphylaxis and has been in use for the past two decades [27 ▪ ,28].…”

Section: Text Reviewmentioning

confidence: 99%

Biologics to treat anaphylaxis

Yang

2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review The purpose of this literature review was to review the latest use of biologics in the management of anaphylaxis. The methodology was to highlight both the nonbiologic management of anaphylaxis and the biologic management and how they can be used in conjunction with each other. Recent findings As the phenotypes and endotypes of anaphylaxis are better portrayed, it furthers our understanding of the mechanisms of anaphylaxis. New applications of existing biologics to the prevention of anaphylaxis are described. Summary Anaphylaxis is a potentially life-threatening acute hypersensitivity reaction affecting up to 16.8% of the U.S. population. Acute management entails swift identification, removal of the causative agent, and the prevention of cardiovascular collapse, firstly with epinephrine. Adjunctive treatments such as antihistamines work to prevent anaphylaxis from recurring. Biologic management of anaphylaxis involves the use of large-molecule drugs such as monoclonal antibodies. Omalizumab, an IgG1 monoclonal antibody targeting unbound IgE, is the most prevalent and widely studied biologic in the prevention of anaphylaxis. Other monoclonal antibodies in development or approved for other indications, such as ligelizumab, quilizumab, MEDI4212, and dupilumab, may also have potential for preventing anaphylaxis through various mechanisms.

show abstract

Biologicals for the prevention of anaphylaxis

Cited by 8 publications

References 53 publications

An update on recent developments and highlights in food allergy

An update on recent developments and highlights in food allergy

An update on recent developments and highlights in food allergy

Biologics to treat anaphylaxis

Contact Info

Product

Resources

About